BUSINESS
Zomato hits 22-month high after 2nd quarter in profit; market value tops Rs 1 lakh cr
Zomato posted a net profit of Rs 36 crore, while revenue grew 71 percent on year to Rs 2,848 crore. The growth comes at a time when the e-commerce sector is facing the inflation heat and muted demand
BUSINESS
F&O Manual | Nifty resumes uptrend for second day but faces resistance at 19,300
Market breadth is tilted heavily in favour of gainers as more than two stocks rose for each one that fell.
BUSINESS
F&O Manual | Nifty inches higher but upside limited as call writers active at 19,150
The 19,100 strike emerged as a battleground for the bulls and bears, with the Nifty coming off the day's high to slip below that level in the cash market
BUSINESS
Sun Pharma's healthy Q2, stellar specialty sales impresses brokerages, triggers hikes in target prices
The healthy earnings growth for Sun Pharma was aided by strong global specialty sales and an industry-beating performance in the domestic market even as US sales faltered sequentially.
BUSINESS
Sun Pharma Q2 Preview: Earnings growth seen muted as Revlimid sales taper off
US sales for Sun Pharma are likely to remain under pressure due to a moderation in contribution from the blockbuster cancer drug Revlimid amidst regulatory snags at the Halol and Mohali plants.
BUSINESS
Mid-day Mood | Gains in heavyweights help indices recover from early losses
Gains in heavyweight counters like Reliance Industries, Tata Consultancy Services, HDFC Bank and ICICI Bank helped lift benchmark indices to their day's high
BUSINESS
Brokerages predict multiple headwinds for Dr Reddy's Labs despite stellar Q2 results
Dr Reddy's Laboratories delivered its highest ever net profit and revenue in the July-September quarter. Both revenue and net profit also topped the Street's expectations in Q2.
BUSINESS
Brokerages bullish on Cipla on better-than-expected Q2 results, hike in margin guidance
Cipla's management raised its margin guidance for FY23 for a second time in a row to 24 percent.
BUSINESS
Cipla Q2 Preview: Another quarter of steady growth, margins to improve
Cipla's strong growth in its chronic therapies and over-the-counter consumer segment is likely to offset the weakness in sales of acute drugs in the domestic market
BUSINESS
Dr Reddy's Q2 preview: Revenue, net profit to rise as Revlimid sales to boost US growth
Despite resilient growth on a year-on-year basis, Dr Reddy's is likely to see some moderation in earnings sequentially
BUSINESS
How will the surge in US bond yields rub-off on other asset classes?
US bond yields have reached the highest level since 2007. Interestingly, in a break from tradition, gold and crude prices are also rising along with the yields, thanks to the global geopolitical uncertainties.
BUSINESS
Brokerages forecast strong growth for Torrent Pharma after robust Q2 show
Torrent Pharma's net profit for the July-September quarter topped estimate, while revenue was largely in-line with expectations.
BUSINESS
ITC falls on fear of near-term earnings, volumes moderation but brokerages bullish
ITC's strong growth in the September quarter was led by FMCG, stationery, cigarettes and hotels business, while agriculture and paperboard segments remained weak
BUSINESS
Mid-Day Mood | Spike in US bond yields pushes indices into red; corporate earnings in focus
Even in a day of weak market action, gains in select blue-chip stocks powered by their stellar July-September earnings helped the benchmark indices recoup some of their losses and come off the day's lows.
BUSINESS
Pharma Q2 preview: Growth moderates amid weak domestic sales, but US to sustain strong momentum
Drugmakers are set to gain from the continuing benefits of Revlimid and other key launches as well as easing price pressure in the US market.
BUSINESS
Mid-day Mood | Broad-based gains lift indices to the day's high; Nifty tops 19,850
Upbeat global cues along with broad-based gains across sectors pushed the market higher. More than two stocks gained for each stock that traded lower — about 2,102 shares gained, 1,004 fell and 135 were unchanged
BUSINESS
Domestic pharma sales pick up in September, but not enough to lift Q2 sales
Despite witnessing a late recovery in September, domestic pharma sales moderated sequentially in Q2, which is likely to put pressure on the July-September earnings of drugmakers
BUSINESS
Mid-day Mood | Indices struggle with losses as IT, banks spoil mood; Nifty below 19,700
Index heavyweight stocks, Infosys, Reliance, Axis Bank and ICICI Bank were trading with cuts which put further pressure on the benchmarks.
BUSINESS
Israel-Hamas conflict may boost Indian defence exports, stocks eyed
Israel is a major trade partner for India and beyond that the two countries have ventured into a significant number of strategic, military, and technology partnerships making them reliable allies of each other.
BUSINESS
As diagnostics price wars ease, some new-age holdouts keep up pressure on older rivals
Analysts said the race to the bottom seems to be over and there appears to be a clear shift in the sector, with prices increasing gradually
BUSINESS
Mid-day Mood | Indices unfazed as RBI policy along expected lines, Nifty firm above 19,600
Most rate-sensitive sectors traded a tad higher after the RBI as expected, left the key repo rate unchanged for the fourth straight time.
BUSINESS
Bumpy October F&O series ahead for Nifty as short rollovers surge, FIIs unwind longs
The double whammy of shorts rollover and FIIs’ falling long positions amidst a slew of key events including the Reserve Bank of India's monetary policy meeting, the MSCI rejig and July-September earnings paints the picture of a volatile October for Nifty.
BUSINESS
Mid-day Mood | Indices back in the red; spike in US bond yields, stronger dollar dampen sentiment
A spike in the US benchmark 10-year bonds yield to the highest level since 2007, the dollar index rising above 107 and sustained selling from foreign institutional investors were the majors factors dragging the market
BUSINESS
Diagnostic players shun discounts, opt for the premium route
Most new-age diagnostic players moved away from heavy discounts and are now raising prices. With this, the difference in pricing between incumbents and established players is narrowing and moving towards a level-playing field
